Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells

Virology

Volumn 291, Issue 2, 2001, Pages 272-284

  Fang, Zhi Yu ^a   Limbach, Keith ^b   Tartaglia, James ^c   Hammonds, Jason ^a   Chen, Xuemin ^a   Spearman, Paul ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Virogenetics Corporation   (United States)

^c Aventis Pasteur   (Canada)

Author keywords

Canarypox virus; E3L; HIV vaccine; HIV 1; K3L; PKR; Pseudovirion

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHICKEN; CONTROLLED STUDY; ELECTRON MICROSCOPY; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION;

CANARYPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; POXVIRIDAE; VACCINIA VIRUS;

EID: 0035692405     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1209     Document Type: Article

References (41)

1. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions
2. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
3. Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene
4. Host-range restriction of vaccinia virus E3L-specific deletion mutants
5. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L-mutant viruses
6. Vaccinia virus-encoded elF-2 alpha homolog abrogates the antiviral effect of interferon
7. Processing of engulfed apoptotic bodies yields T cell epitopes
8. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
9. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms
10. The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2
11. + cytotoxic T lymphocyte responses in seronegative volunteers
12. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
13. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
14. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160
15. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase
16. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion
17. Proteins that interact with PKR
18. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
19. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis
20. DNA and RNA-based vaccines: Principles, progress and prospects
21. Progress in the development of an HIV-1 vaccine
22. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus
23. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
24. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates
25. Human trials of HIV-1 vaccines
26. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
27. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system
28. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
29. + lymphocytes
30. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice
31. Retroviruses of human AIDS and related animal diseases
32. Highly attenuated poxvirus vectors
33. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
34. NYVAC: A highly attenuated strain of vaccinia virus
35. Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR
36. Biological and immunogenic properties of a canarypox-rabies recombinant. ALVAC-RG (vCP65) in non-avian species
37. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
38. Characterization of a vaccinia virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded RNA-dependent protein kinase
39. elF-2 kinases: Regulators of general and gene-specific translation initiation
40. A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR
41. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells